Search

Orobanche crenata seeds, collected in Syria, Egypt and Spain, were buried in the field in Syria (all three seed lots) and Spain (only Spanish seeds) and at regular intervals exhumed and tested for germination, to investigate whether the seeds exhibit an annual dormancy/non-dormancy cycle. When exposed directly to the synthetic germination stimulant GR24 for 7 days at 20°C, seeds only germinated in autumn after the first rains and to a limited extent in winter. When the seeds were conditioned for 11 days at 20°C prior to exposure to GR24, germination occurred during summer and autumn, but seeds were dormant in winter and early spring. The observed seasonal pattern in germinability, in relation to rainfall and soil temperature, was largely consistent with the results of an in vitro experiment by Van Hezewijk et al. (1993), investigating the effect of conditioning temperature and conditioning period on germination capacity and the development of secondary dormancy. Moisture and temperature can therefore be considered the major factors regulating induction and alleviation of dormancy in buried O. crenata seeds. There were no basic differences in response owing to site of collection of O. crenata seeds, nor to the location where they were buried. [ABSTRACT FROM AUTHOR]

Background and Objective: Irritable Bowel Syndrome (IBS) has a substantial impact on health-related quality of life (HR-QoL) but high-quality data pre- and post-treatment using the IBS-Quality of Life (IBS-QOL) measure are limited. The objective of this study was to evaluate the changes from baseline of the IBS-QOL scores, symptom scores and health economic data in IBS patients, after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide., Methods: This was a prospective observational cohort study in patients with IBS, diagnosed using the Rome III criteria in four countries (Poland, Egypt, Mexico and China)., Results: A total of 607 patients were enrolled. At baseline, the IBS-QOL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China and 56.4 overall. Increases in IBS-QOL total score were statistically significant at Weeks 4 and 8 overall and in each country (overall: 11.8 at Week 4, 24.3 at Week 8; p < 0.001). Improvements were shown in all IBS-QOL subscales and scores. Symptoms and health economic outcomes were improved. Furthermore, the favourable safety profile of these treatments was confirmed in this study., Conclusions: This study demonstrated that IBS patients have a substantially reduced HR-QoL and that treatment with mebeverine hydrochloride or pinaverium bromide improved HR-QoL.